Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Treg Cells and Everolimus in Renal Transplant
NCT03284242Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous regulatory T cells in kidney transplant rejection. Primary endpoints: Changes in Tregs Infusion Toxicities, Changes in Kidney Function at 2 years and 2 more. Started Mar 2019; status: completed.
02
Drugs
autologous regulatory T cells
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03284242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284242.